Europe risks falling further behind the United States and China in pharmaceutical research and innovation because of “mind-blowing” bureaucracy and government policies threatening jobs, Roche Chief Executive Thomas Schinecker warned on Thursday.
His comments come as drugmakers weigh the impact of U.S. President Donald Trump’s “most-favored-nation” pricing push, which aims to tie some medicine prices in the lucrative U.S. market to lower prices elsewhere, including in Europe. Since the policy
